Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

BioCryst Pharmaceuticals stock climbs 9% on strong Orladeyo sales, 2025 revenue guidance boost, and market dominance. See why ...

The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at ...

Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...

Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...

One of Australia's biggest pathology providers reports that GP visits and pathology volumes remain well below the historical ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

William Blair issued their Q1 2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the ...

The nonprofit foundation, n-Lorem developed personalized medicine for a child with rare leukodystrophy.

Rockland Immunochemicals, Inc. is pleased to announce that Dr. David P. Chimento, Vice President of Research and Development, Amy L. Anderson, Technical Applications Specialist, and Dr. Carl Ascoli, ...